STC1 and neoplasm: In lung cancer, STC1 expression is negatively correlated with immunotherapeutic effects and contributes to anti-tumor immune cell activity in the tumor microenvironment (TME) by affecting tumor immune evasion and immunotherapy resistance (Lin et al., 2021).